Sciwind Biosciences Deal History & Licensing Activity
Sciwind Biosciences is a life sciences. Over the past three years, Sciwind Biosciences has been involved in 6 licensing and acquisition transactions, with a primary focus on Peptides (8 deals). The company currently has 4 active clinical trials, primarily in Option Deals.
Deals (12mo)
1
Active Trials
4
Top Modality
Peptides
Focus Area
Option Deals
Sciwind Biosciences Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sciwind Biosciences in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| ecnoglutide | Pfizer | Peptides | Approved | license | Feb 2026 |
| incretin/GLP-1 metabolic assets | Verdiva Bio | Peptides | Preclinical | option | Jun 2025 |
| metabolic disease pipeline (oral GLP-1, amylin agonist) | Verdiva Bio | Peptides | Preclinical | license | Jun 2025 |
Sciwind Biosciences Pipeline Focus
Therapeutic areas and modalities where Sciwind Biosciences is most active based on deal history and clinical trial data.
Sciwind Biosciences Strategic Signals
Key indicators of Sciwind Biosciences's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Sciwind Biosciences Clinical Pipeline
Sciwind Biosciences has 4 active clinical trials across 3 development phases.
1
Phase 1
1
Phase 2
2
Phase 3
See How Your Asset Matches Sciwind Biosciences's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Option Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Sciwind Biosciences Licensing & Deal Activity
Sciwind Biosciences is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 6 deals over the past three years, Sciwind Biosciences ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sciwind Biosciences include Option Deals (8 deals and trials), Metabolic (6 deals and trials), and Codev Deals (2 deals and trials). In terms of modality, Sciwind Biosciences has shown particular interest in peptides, other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sciwind Biosciences and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Sciwind Biosciences's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.